[go: up one dir, main page]

PL2887923T3 - Preparat okulistyczny polioksylipidu lub polioksylowego kwasu tłuszczowego i leczenie chorób oczu - Google Patents

Preparat okulistyczny polioksylipidu lub polioksylowego kwasu tłuszczowego i leczenie chorób oczu

Info

Publication number
PL2887923T3
PL2887923T3 PL13831463.8T PL13831463T PL2887923T3 PL 2887923 T3 PL2887923 T3 PL 2887923T3 PL 13831463 T PL13831463 T PL 13831463T PL 2887923 T3 PL2887923 T3 PL 2887923T3
Authority
PL
Poland
Prior art keywords
polyoxyl
treatment
fatty acid
ophthalmic formulation
ocular conditions
Prior art date
Application number
PL13831463.8T
Other languages
English (en)
Inventor
Ashim K. Mitra
Sidney L. WEISS
Eugene J. Mcnally
Original Assignee
Sun Pharmaceutical Industries Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=50148510&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL2887923(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Sun Pharmaceutical Industries Limited filed Critical Sun Pharmaceutical Industries Limited
Publication of PL2887923T3 publication Critical patent/PL2887923T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A61K38/13—Cyclosporins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Ophthalmology & Optometry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Dispersion Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
PL13831463.8T 2012-08-24 2013-08-23 Preparat okulistyczny polioksylipidu lub polioksylowego kwasu tłuszczowego i leczenie chorób oczu PL2887923T3 (pl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261693189P 2012-08-24 2012-08-24
PCT/US2013/056513 WO2014032026A1 (en) 2012-08-24 2013-08-23 Ophthalmic formulation of polyoxyl lipid or polyoxyl fatty acid and treatment of ocular conditions

Publications (1)

Publication Number Publication Date
PL2887923T3 true PL2887923T3 (pl) 2023-08-14

Family

ID=50148510

Family Applications (1)

Application Number Title Priority Date Filing Date
PL13831463.8T PL2887923T3 (pl) 2012-08-24 2013-08-23 Preparat okulistyczny polioksylipidu lub polioksylowego kwasu tłuszczowego i leczenie chorób oczu

Country Status (16)

Country Link
US (5) US8980839B2 (pl)
EP (2) EP4218729A1 (pl)
AU (1) AU2013305539B2 (pl)
CA (2) CA3050298A1 (pl)
DK (1) DK2887923T3 (pl)
ES (1) ES2948387T3 (pl)
FI (1) FI2887923T3 (pl)
HK (1) HK1211867A1 (pl)
HR (1) HRP20230559T1 (pl)
HU (1) HUE062145T2 (pl)
LT (1) LT2887923T (pl)
MX (1) MX361858B (pl)
PL (1) PL2887923T3 (pl)
PT (1) PT2887923T (pl)
SI (1) SI2887923T1 (pl)
WO (1) WO2014032026A1 (pl)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4218729A1 (en) 2012-08-24 2023-08-02 Sun Pharmaceutical Industries Limited Topical formulations and uses thereof
WO2015179527A1 (en) * 2014-05-23 2015-11-26 Ocular Technologies Sarl Topical formulations and uses thereof
WO2016172712A2 (en) 2015-04-23 2016-10-27 Sydnexis, Inc. Ophthalmic composition
US9421199B2 (en) 2014-06-24 2016-08-23 Sydnexis, Inc. Ophthalmic composition
WO2016028800A1 (en) * 2014-08-20 2016-02-25 A.T. Resolve Sarl Treatment of corneal haze
US11382909B2 (en) 2014-09-05 2022-07-12 Sydnexis, Inc. Ophthalmic composition
KR101587412B1 (ko) * 2014-10-17 2016-01-21 주식회사 휴온스 사이클로스포린 및 트레할로스를 포함하는 안과용 조성물
WO2016178881A1 (en) * 2015-05-04 2016-11-10 Ocular Technologies Sarl Topical formulations and uses thereof
WO2016196367A1 (en) * 2015-05-29 2016-12-08 Sydnexis, Inc. D2o stabilized pharmaceutical formulations
US20190231885A1 (en) * 2015-11-10 2019-08-01 Sun Pharma Global Fze Topical formulations and uses thereof
US20180333352A1 (en) * 2015-11-12 2018-11-22 Sun Pharma Global Fze Topical formulations and uses thereof
DK3423076T3 (da) 2016-02-29 2024-07-08 Sun Pharmaceutical Ind Ltd Topisk cyclosporinholdige formuleringer og anvendelser deraf
US10207003B2 (en) 2016-04-29 2019-02-19 inovion, Inc. Liquid pentablock co-polymer formulations for sustained delivery of therapeutics
US11135311B2 (en) * 2016-11-29 2021-10-05 Oculis SA Preparation of solid cyclodextrin complexes for ophthalmic active pharmaceutical ingredient delivery
CN107334734B (zh) * 2017-07-10 2020-03-17 浙江大学 一种西罗莫司或其衍生物的眼用制剂
KR102704402B1 (ko) 2018-10-24 2024-09-06 (주)아모레퍼시픽 피부장벽 강화용 조성물
CN114040766A (zh) 2019-07-01 2022-02-11 奥库里斯公司 用于稳定包含药物的水性组合物pH的方法
US20230172946A1 (en) * 2019-08-18 2023-06-08 Iview Therapeutics, Inc. In-situ Gel Forming Ophthalmic Formulations Containing Difluprednate
CN115038434A (zh) * 2019-12-09 2022-09-09 路易斯安娜州立大学监测委员会，农业和机械学院 用于治疗角膜病变的生物分子
US11918275B2 (en) 2021-04-30 2024-03-05 Cilag Gmbh International Electrosurgical adaptation techniques of energy modality for combination electrosurgical instruments based on shorting or tissue impedance irregularity
KR20220159751A (ko) 2021-05-26 2022-12-05 (주)아모레퍼시픽 미백용 조성물 및 이를 이용한 피부 미백방법
JP2024521968A (ja) 2021-06-14 2024-06-04 サン ファーマシューティカル インダストリーズ リミテッド 白内障手術を受ける患者において使用するための、シクロスポリン製剤
IL310823A (en) * 2021-08-20 2024-04-01 Sun Pharmaceutical Ind Ltd Stable cyclosporine ophthalmic formulation and manufacturing process thereof

Family Cites Families (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2406A (en) * 1841-12-30 Construction of railroad-scbapers fob cleaning te-ie tracks from sl
FR520E (fr) 1901-11-13 1903-01-26 Bermont Victor Etienne Procédé industriel d'extraction directe du zinc contenu dans les minerais oxydés, et plus spécialement dans la smithsonite (znco3) et la calamine (h2zn2sio5)
HK1004520A1 (en) 1992-05-13 1998-11-27 Novartis Ag Ophthalmic compositions containing a cyclosporin
NZ247516A (en) * 1993-04-28 1995-02-24 Bernard Charles Sherman Water dispersible pharmaceutical compositions comprising drug dissolved in solvent system comprising at least one alcohol and at least one surfactant
US5484597A (en) 1993-07-30 1996-01-16 Chesebrough-Pond's Usa Co. Clear hydroalcholic cosmetic microemulsions
NZ280689A (en) * 1995-12-15 1997-08-22 Bernard Charles Sherma Sherman Pharmaceutical composition comprising a cyclosporipharmaceutical composition comprising a cyclosporin; a tocol, tocopherol or tocotrienol; and propylen; a tocol, tocopherol or tocotrienol; and propylene carbonate or polyethylene glycol ne carbonate or polyethylene glycol
MX9701946A (es) 1997-03-14 1998-04-30 Arturo Jimenez Bayardo Solucion oftalmica transportadora.
US6816968B1 (en) * 1998-07-10 2004-11-09 Silverbrook Research Pty Ltd Consumable authentication protocol and system
US7678836B2 (en) * 1999-11-04 2010-03-16 Fxs Ventures, Llc Method for rendering a contact lens wettable
US7732404B2 (en) * 1999-12-30 2010-06-08 Dexcel Ltd Pro-nanodispersion for the delivery of cyclosporin
EP1296923B3 (en) 2000-02-16 2012-04-11 The Brigham And Women's Hospital, Inc. Aspirin-triggered lipid mediators
US20030176356A1 (en) 2001-04-24 2003-09-18 University Of North Texas Health Science Center Endothelin antagonists and endothelin-converting enzyme inhibitors for the treatment of glaucoma
EP2116228A1 (en) 2001-10-19 2009-11-11 Isotechnika Inc. Novel cyclosporin analog microemulsion preconcentrates
AU2002365167A1 (en) 2001-12-18 2003-07-09 The Brigham And Women's Hospital Inhibition or prevention of infection by bacteria with epa, dha or analogs
US7582785B2 (en) 2002-04-01 2009-09-01 University Of Southern California Trihydroxy polyunsaturated eicosanoid derivatives
ES2527753T3 (es) 2002-04-01 2015-01-29 University Of Southern California Eicosanoides trihidroxi poliinsaturados
US7759395B2 (en) 2002-08-12 2010-07-20 The Brigham And Women's Hospital, Inc. Use of docosatrienes, resolvins and their stable analogs in the treatment of airway diseases and asthma
EP1537067B1 (en) 2002-08-12 2009-11-18 Brigham And Women's Hospital Resolvins: biotemplates for therapeutic interventions
WO2004069181A2 (en) 2003-02-03 2004-08-19 Pharmacia Corporation Composition for the treatment of intraocular pressure
JP2004238346A (ja) 2003-02-07 2004-08-26 Shiono Chemical Co Ltd トラニラストの安定な水溶液製剤
WO2004078143A2 (en) 2003-03-05 2004-09-16 The Brigham And Women's Hospital Inc. Methods for identification and uses of anti-inflammatory receptors for eicosapentaenoic acid analogs
AU2003228126A1 (en) 2003-05-02 2004-11-23 Arturo Jimenez Bayardo Method of preparing an aqueous solution of cyclosporin-a and resulting aqueous solution
US7087237B2 (en) * 2003-09-19 2006-08-08 Advanced Ocular Systems Limited Ocular solutions
US20050238589A1 (en) 2004-04-14 2005-10-27 Van Dyke Thomas E Methods and compositions for preventing or treating periodontal diseases
US20060020563A1 (en) * 2004-07-26 2006-01-26 Coleman Christopher R Supervised neural network for encoding continuous curves
ATE412400T1 (de) * 2004-11-09 2008-11-15 Novagali Pharma Sa Öl-in-wasser-emulsion mit niedriger konzentration des kationischen mittels und positivem zetapotential
KR20070090928A (ko) 2004-11-19 2007-09-06 마텍 바이오싸이언스스 코포레이션 장쇄 다가불포화 지방산으로부터의 옥시리핀, 및 이의 제조방법 및 사용 방법
KR20080029974A (ko) 2005-06-09 2008-04-03 산텐 세이야꾸 가부시키가이샤 로플루밀라스트 점안액
EP1890677A4 (en) 2005-06-16 2013-01-30 Myriad Genetics Inc PHARMACEUTICAL COMPOSITIONS AND THEIR USE
US20070015691A1 (en) 2005-07-13 2007-01-18 Allergan, Inc. Cyclosporin compositions
WO2007011880A2 (en) 2005-07-18 2007-01-25 Minu, L.L.C. Enhanced ocular neuroprotection/neurostimulation
US20090320148A1 (en) 2006-01-31 2009-12-24 Martek Biosciences Corporation Oxylipins from stearidonic acid and gamma-linolenic acid and methods of making and using the same
US10137083B2 (en) * 2006-03-07 2018-11-27 SGN Nanopharma Inc Ophthalmic preparations
FR2904568B1 (fr) * 2006-08-03 2008-09-05 Dynastar Skis Sa Procede de fabrication d'une planche de glisse
US20110190389A1 (en) 2007-02-20 2011-08-04 Linda Arterburn Oxylipins from long chain polyunsaturated fatty acids and methods of making and using the same
US20100310462A1 (en) 2007-04-18 2010-12-09 Biochromix Ab Binding of pathological forms of proteins using conjugated polyelectrolytes
US8512687B2 (en) * 2007-07-09 2013-08-20 Novagali Pharma Sa Oil in water emulsion comprising NSAIDs and quaternary ammonium halides
US20090048929A1 (en) * 2007-08-15 2009-02-19 Paul Im Authenticated travel record
ES2511840T3 (es) 2007-08-29 2014-10-23 Wakamoto Pharmaceutical Co., Ltd. Composición farmacéutica acuosa que contiene latanoprost
MX2007011165A (es) 2007-09-12 2009-03-11 Arturo Jimenez Bayardo Composición farmacéutica estable de timolol, dorzolamida y brimonidina.
CN101918019B (zh) * 2007-10-08 2014-11-26 奥里尼亚制药有限公司 包含钙调神经磷酸酶抑制剂或mTOR抑制剂的眼科组合物
CA2710843A1 (en) * 2008-01-04 2009-07-16 Alcon Pharmaceuticals Ltd. Stable aqueous cyclosporin compositions
TWI544927B (zh) * 2008-03-17 2016-08-11 愛爾康研究有限公司 具有低濃度的表面活性劑以促進治療劑之生物可利用性的藥學組成物
BRPI0912302A2 (pt) * 2008-05-28 2015-10-20 Alcon Res Ltd emulsões autopreservados
EP2127638A1 (en) * 2008-05-30 2009-12-02 Santen Pharmaceutical Co., Ltd Method and composition for treating ocular hypertension and glaucoma
AP2012006053A0 (en) * 2009-06-02 2012-02-29 Brian Charles Keller Pure peg-lipid conjugates.
CN102458370A (zh) * 2009-06-09 2012-05-16 卢克斯生物科技公司 用于眼科用途的表面药物递送系统
CA2773597A1 (en) * 2009-09-17 2011-03-24 Senju Pharmaceutical Co., Ltd. Latanoprost-containing aqueous eye drops and method for inhibiting adsorption of latanoprost to resin
US8637569B2 (en) 2009-10-22 2014-01-28 Api Genesis, Llc Methods of increasing solubility of poorly soluble compounds and methods of making and using formulations of such compounds
US9328162B2 (en) 2010-02-25 2016-05-03 Schepens Eye Research Institute Therapeutic compositions for the treatment of dry eye disease
CA2798923A1 (en) 2010-05-07 2011-11-10 Sun Pharma Advanced Research Company Ltd. Novel ophthalmic compositions
US20130065888A1 (en) 2011-08-15 2013-03-14 Biserka Cetina-Cizmek Ophthalmic formulations and processes for their preparation
KR101211902B1 (ko) 2012-04-30 2012-12-13 주식회사 휴온스 사이클로스포린 함유 무자극성 나노에멀젼 안약 조성물
CA2872958A1 (en) 2012-05-11 2013-11-14 Cipla Limited Pharmaceutical composition
EP4218729A1 (en) 2012-08-24 2023-08-02 Sun Pharmaceutical Industries Limited Topical formulations and uses thereof
US10946076B2 (en) 2013-02-13 2021-03-16 The Research Foundation For The State University Of New York Glaucoma treatment
WO2015179527A1 (en) 2014-05-23 2015-11-26 Ocular Technologies Sarl Topical formulations and uses thereof
US9421199B2 (en) 2014-06-24 2016-08-23 Sydnexis, Inc. Ophthalmic composition
WO2016178881A1 (en) 2015-05-04 2016-11-10 Ocular Technologies Sarl Topical formulations and uses thereof
US20190231885A1 (en) 2015-11-10 2019-08-01 Sun Pharma Global Fze Topical formulations and uses thereof
US20180333352A1 (en) 2015-11-12 2018-11-22 Sun Pharma Global Fze Topical formulations and uses thereof
DK3423076T3 (da) 2016-02-29 2024-07-08 Sun Pharmaceutical Ind Ltd Topisk cyclosporinholdige formuleringer og anvendelser deraf
WO2017152129A2 (en) 2016-03-03 2017-09-08 Ocular Technologies Sarl Treatment of glaucoma and/or retinal diseases and formulations useful therefore

Also Published As

Publication number Publication date
ES2948387T3 (es) 2023-09-11
CA3050298A1 (en) 2014-02-27
US20160256520A1 (en) 2016-09-08
DK2887923T3 (da) 2023-07-03
HRP20230559T1 (hr) 2023-09-15
CA2914472A1 (en) 2014-02-27
EP2887923A4 (en) 2016-03-30
CA2914472C (en) 2019-09-03
SI2887923T1 (sl) 2023-09-29
EP4218729A1 (en) 2023-08-02
HUE062145T2 (hu) 2023-10-28
US20140057854A1 (en) 2014-02-27
EP2887923B1 (en) 2023-04-05
US20150148299A1 (en) 2015-05-28
MX2015002239A (es) 2016-01-08
US20160256521A1 (en) 2016-09-08
AU2013305539B2 (en) 2018-08-02
PT2887923T (pt) 2023-06-28
MX361858B (es) 2018-12-18
WO2014032026A1 (en) 2014-02-27
LT2887923T (lt) 2023-07-10
US20150165048A1 (en) 2015-06-18
US8980839B2 (en) 2015-03-17
FI2887923T3 (fi) 2023-06-30
HK1211867A1 (en) 2016-06-03
AU2013305539A1 (en) 2015-03-12
US10441630B2 (en) 2019-10-15
US9937225B2 (en) 2018-04-10
EP2887923A1 (en) 2015-07-01

Similar Documents

Publication Publication Date Title
SI2887923T1 (sl) Oftalmična formulacija polioksilnega lipida ali polioksilne maščobne kisline in zdravljenje očesnih stanj
IL260585B (en) Compositions and methods for treating retinal diseases
IL238432B (en) Methods and devices for the treatment of eye diseases in humans
BR112012032948A2 (pt) dispositivos injectores e método de suprimento de solução oftálmica à córnea do olho
ZA201402615B (en) Prevention and treatment of ocular conditions
ZA201408592B (en) Methods for the treatment of diabetic retinopathy and other ophthalmic diseases
IL234759A0 (en) Aqueous herbicide concentrates containing fatty acid alkyl esters, fatty acid amides, or fatty acid esters in the triglyceride configuration and methods of use
IL236221A (en) History of theophyridone and pharmacological preparations containing them for the treatment of diseases
IL230957A0 (en) Pharmacy methods and preparations for the treatment of an eye disease in a patient
HUE046963T2 (hu) Készítmények és kezelés szembetegségekhez és rendellenességekhez
IL235762A0 (en) Stable emulsion to prevent skin irritation and items that use it
IL235765A0 (en) Stable emulsion to prevent skin irritation and items that use it
PL3556346T3 (pl) Estry do leczenia stanów zapalnych oczu
PL2814463T3 (pl) Okulistyczne kompozycje farmaceutyczne i sposoby ich wytwarzania i stosowania
IL231374A (en) Use of epa and dha to treat eye disease
EP2906295A4 (en) METHODS OF TREATING OCULAR DISEASES
IL235874A0 (en) Treatment of ocular inflammatory diseases by laquinimod
ZA201408993B (en) Pharmaceutical formulation for bedwetting and method of use thereof
PT2603238E (pt) Métodos e composições farmacêuticas para o tratamento de uma doença ocular num indíviduo
EP3013425A4 (en) Treatment and diagnosis of ocular disease
EP2934285A4 (en) METHOD AND SYSTEMS FOR DIAGNOSIS OF EYE DISEASES
EP2734188A4 (en) COMPOSITIONS AND METHOD FOR THE TREATMENT OF EYE SURFACE ALLERGIES
IL239078A0 (en) Protein for use in the treatment of eye diseases
IL239512B (en) Analogues and derivatives of alkyl fatty acids, pharmaceutical formulations containing them and their uses
GB201223337D0 (en) Treatment of non eye infections and non refractive disorders